Literature DB >> 9362320

Lack of cross tolerance between LPS and muramyl dipeptide in induction of circulating TNF-alpha and IL-6 in guinea pigs.

J Roth1, T Aslan, B Störr, E Zeisberger.   

Abstract

In guinea pigs, lipopolysaccharide (LPS) from gram-negative bacteria and muramyl dipeptide (MDP) from gram-positive bacteria are potent inducers of systemic production of proinflammatory cytokines and fever. However, there is a striking difference between these two bacterial pyrogens in so far as repeated administration of LPS, but not of MDP, in short-term intervals induces tolerance by a progressive downregulation of the systemic cytokine network. In the present study, we investigated MDP-induced fever and the systemic release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in LPS-tolerant guinea pigs in comparison with naive animals. Endotoxin tolerance was induced by repeated intramuscular injections of 20 microg/kg LPS at intervals of 3 days. In response to the last of five injections with LPS, systemic production of TNF-alpha and IL-6 as well as the development of a febrile response was abrogated almost completely. Those guinea pigs that had developed an LPS tolerance could, however, produce the same amounts of TNF-alpha and IL-6 as naive animals in response to a challenge with MDP. Also, MDP-induced fever was identical in LPS-tolerant and naive guinea pigs. These results provide evidence for a lack of cross tolerance between LPS and MDP in induction of circulating cytokines and fever in guinea pigs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362320     DOI: 10.1152/ajpregu.1997.273.4.R1529

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Location-specific activation of the paraventricular nucleus of the hypothalamus by localized inflammation.

Authors:  Natalya Belevych; Krystal Buchanan; Qun Chen; Michael Bailey; Ning Quan
Journal:  Brain Behav Immun       Date:  2010-05-31       Impact factor: 7.217

Review 2.  A review of the physiology of fever in birds.

Authors:  David A Gray; Manette Marais; Shane K Maloney
Journal:  J Comp Physiol B       Date:  2012-11-18       Impact factor: 2.200

Review 3.  MicroRNA in TLR signaling and endotoxin tolerance.

Authors:  Md A Nahid; Minoru Satoh; Edward Kl Chan
Journal:  Cell Mol Immunol       Date:  2011-08-08       Impact factor: 11.530

4.  Evaluation of iNOS-dependent and independent mechanisms of the microvascular permeability change induced by lipopolysaccharide.

Authors:  E Fujii; T Yoshioka; H Ishida; K Irie; T Muraki
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Neonatal programming of the rat neuroimmune response: stimulus specific changes elicited by bacterial and viral mimetics.

Authors:  Shaun Ellis; Abdeslam Mouihate; Quentin J Pittman
Journal:  J Physiol       Date:  2006-01-19       Impact factor: 5.182

6.  Differential regulation of membrane CD14 expression and endotoxin-tolerance in alveolar macrophages.

Authors:  Shu-Min Lin; Charles W Frevert; Osamu Kajikawa; Mark M Wurfel; Kimberly Ballman; Stephen Mongovin; Venus A Wong; Amy Selk; Thomas R Martin
Journal:  Am J Respir Cell Mol Biol       Date:  2004-04-01       Impact factor: 6.914

7.  Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses.

Authors:  Ursula Deiters; Marina Gumenscheimer; Chris Galanos; Peter F Mühlradt
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

8.  Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.

Authors:  Diego Bertoli; Federico Serana; Alessandra Sottini; Cinzia Cordioli; Davide Maimone; Maria Pia Amato; Diego Centonze; Ciro Florio; Elisa Puma; Ruggero Capra; Luisa Imberti
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.